Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: golimumab
DATE: 27/11/2025
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
